Search results for "EUROPEAN GUIDELINES"

showing 4 items of 4 documents

Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.

2015

Peer reviewed

0301 basic medicineAdultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmenteducationPain5-AMINOLEVULINIC ACIDHuman skinPhotodynamic therapyPilot ProjectsEUROPEAN GUIDELINESDermatology030105 genetics & heredityAdministration Cutaneousphotodynamic therapy (PDT)ihosyöpä03 medical and health sciencesDouble-Blind MethodMedicineHumansPhotosensitizerProdrugsSkinACTINIC KERATOSESihoPhotosensitizing Agentsbusiness.industryGeneral MedicineActinic keratosesAminolevulinic AcidDermatologyHealthy Volunteers3. Good healthOikeuslääketiede ja muut lääketieteet - Forensic science and other medical sciencesREDUCES INFLAMMATIONPhotochemotherapyErythema3121 General medicine internal medicine and other clinical medicinebusinessActa dermato-venereologica
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Hexyl aminolevulinate, 5‐aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non‐aggressive basal cell carcinomas:…

2020

Background In the photodynamic therapy (PDT) of non‐aggressive basal cell carcinomas (BCCs), 5‐aminolevulinic acid nanoemulsion (BF‐200ALA) has shown non‐inferior efficacy when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the first study using HAL‐PDT in the treatment of BCCs. Objectives To compare the histological clearance, tolerability (pain and post‐treatment reaction), and cosmetic outcome of MAL, BF‐200 ALA, and low‐concentration HAL in the PDT of non‐aggressive BCCs. Methods Ninety‐eight histologically verified non‐aggressive BCCs met the inclusion criter…

Skin Neoplasmsmedicine.medical_treatmentPhotodynamic therapyGastroenterologylaw.invention030207 dermatology & venereal diseases0302 clinical medicineMethyl aminolevulinateRandomized controlled trialnon-aggressive basal cell carcinomalawTOPICAL IMIQUIMODProspective Studies10. No inequalityProspective cohort studyPhotosensitizing AgentsSisätaudit - Internal medicinePAINkarsinoomat3. Good healthTreatment OutcomeInfectious Diseasesphotodynamic therapyTolerabilityFluorouracil030220 oncology & carcinogenesisBOWENS-DISEASEmedicine.symptommedicine.drugmedicine.medical_specialtyBiolääketieteet - Biomedicine3122 Cancersmethyl aminolevulinateEUROPEAN GUIDELINESDermatologySINGLE-BLINDLesion03 medical and health scienceshexyl aminolevulinatenon‐aggressive basal cell carcinomaSyöpätaudit - CancersInternal medicineparasitic diseasesMANAGEMENTmedicineCarcinomaHumansANESTHESIAbusiness.industryAminolevulinic Acidmedicine.disease5‐aminolevulinic acid nanoemulsionFLUOROURACILPROTOPORPHYRIN IX FORMATIONfotodynaaminen hoitoPhotochemotherapyCarcinoma Basal Cell5-aminolevulinic acid nanoemulsionbusinessSKINJournal of the European Academy of Dermatology and Venereology
researchProduct

Clinical justification of dental radiology in adult patients: A review of the literature

2007

Although the radiological doses used by dentists are low individually, patients are often exposured to many repeat dental radiographic examinations. The ‘routine’ use of dental radiography, such as screening of all patients using dental panoramic radiography (DPRs) or a random decision to take a dental radiograph, will inevitable lead to unnecessary patient exposure. The use of Radiographic Referral Criteria has now become a legal requirement for all practitioners following the adoption of European Legislation. All exposures to x-rays should be clinically justified and each exposure should be expected to give the patient a positive net benefit. Recently the European Commission has published…

odontologíaRadiation protectiondentistryregulationsGuías europeasradiología dentalUNESCO::CIENCIAS MÉDICASdental radiologylegislación:CIENCIAS MÉDICAS [UNESCO]European guidelinesProtección radiológica
researchProduct